DHR
Danaher Corporation NYSE Listed Dec 29, 1978$175.64
After hrs
$171.30
+0.08%
Mkt Cap $124.3B
52w Low $172.06
5.1% of range
52w High $242.80
50d MA $190.87
200d MA $208.45
P/E (TTM)
34.5x
EV/EBITDA
25.3x
P/B
2.4x
Debt/Equity
0.3x
ROE
7.0%
P/FCF
30.8x
RSI (14)
—
ATR (14)
—
Beta
0.99
50d MA
$190.87
200d MA
$208.45
Avg Volume
4.4M
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
2200 Pennsylvania Avenue, NW · Washington, DC 20037-1701 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21, 2026 | AMC | 1.94 | 2.06 | +6.2% | 194.54 | -0.3% | -5.4% | -8.2% | -8.9% | -7.2% | -8.0% | — |
| Jan 28, 2026 | AMC | 2.16 | 2.23 | +3.2% | 224.54 | -0.5% | -2.2% | -2.5% | -0.5% | -3.5% | -2.2% | — |
| Oct 21, 2025 | AMC | 1.72 | 1.89 | +9.9% | 220.77 | +0.8% | -1.2% | +0.9% | +1.0% | +0.1% | -1.8% | — |
| Jul 22, 2025 | AMC | 1.64 | 1.80 | +9.8% | 189.91 | +5.6% | +4.2% | +6.8% | +8.2% | +6.9% | +8.9% | — |
| Apr 22, 2025 | AMC | 1.63 | 1.88 | +15.3% | 192.07 | +4.1% | +2.2% | +2.3% | +2.6% | +2.0% | +3.6% | — |
| Jan 29, 2025 | AMC | 2.14 | 2.14 | +0.0% | 223.73 | +0.6% | -0.3% | -0.4% | -4.2% | -3.9% | -5.2% | — |
| Oct 22, 2024 | AMC | 1.57 | 1.71 | +8.9% | 261.28 | -1.1% | -2.0% | -5.1% | -6.1% | -6.6% | -7.1% | — |
| Jul 23, 2024 | AMC | 1.57 | 1.72 | +9.6% | 264.18 | -0.9% | +0.6% | +2.2% | +3.7% | +2.8% | +4.2% | — |
| Apr 23, 2024 | AMC | 1.72 | 1.92 | +11.6% | 253.11 | -1.6% | -1.1% | -2.9% | -2.6% | -2.5% | -2.6% | — |
| Jan 30, 2024 | AMC | 1.90 | 2.09 | +10.0% | 244.95 | +0.3% | -2.1% | +0.1% | +0.6% | +0.4% | +1.3% | — |
| Oct 24, 2023 | AMC | 1.83 | 2.02 | +10.4% | 196.84 | -2.0% | -2.1% | -1.6% | -4.6% | -6.0% | -2.4% | — |
| Jul 25, 2023 | AMC | 2.00 | 2.05 | +2.5% | 226.65 | -0.5% | +3.6% | -0.2% | +1.7% | -0.2% | -0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23 | Morgan Stanley | Maintains | Overweight → Overweight | — | $184.04 | $180.82 | -1.7% | -3.0% | -3.7% | -1.9% | -2.7% | -2.8% |
| Apr 22 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $194.54 | $193.95 | -0.3% | -5.4% | -8.2% | -8.9% | -7.2% | -8.0% |
| Apr 22 | Baird | Maintains | Outperform → Outperform | — | $194.54 | $193.95 | -0.3% | -5.4% | -8.2% | -8.9% | -7.2% | -8.0% |
| Apr 22 | Guggenheim | Maintains | Buy → Buy | — | $194.54 | $193.95 | -0.3% | -5.4% | -8.2% | -8.9% | -7.2% | -8.0% |
| Apr 22 | UBS | Maintains | Buy → Buy | — | $194.54 | $193.95 | -0.3% | -5.4% | -8.2% | -8.9% | -7.2% | -8.0% |
| Apr 17 | Baird | Maintains | Outperform → Outperform | — | $193.78 | $194.58 | +0.4% | +0.5% | +0.9% | +0.4% | -5.0% | -7.8% |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $195.87 | $195.62 | -0.1% | +1.4% | +1.2% | -1.1% | -0.6% | -0.2% |
| Apr 13 | Goldman Sachs | Maintains | Buy → Buy | — | $189.61 | $188.67 | -0.5% | +3.3% | +4.7% | +4.5% | +2.2% | +2.7% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $191.12 | $190.63 | -0.3% | +0.5% | -0.1% | +2.7% | +1.0% | -0.8% |
| Jan 29 | JP Morgan | Maintains | Overweight → Overweight | — | $224.54 | $223.32 | -0.5% | -2.2% | -2.5% | -0.5% | -3.5% | -2.2% |
| Jan 29 | Jefferies | Maintains | Buy → Buy | — | $224.54 | $223.32 | -0.5% | -2.2% | -2.5% | -0.5% | -3.5% | -2.2% |
| Jan 7 | TD Cowen | Maintains | Buy → Buy | — | $236.59 | $236.85 | +0.1% | -0.4% | -0.7% | +0.8% | +1.0% | -0.4% |
| Jan 5 | Guggenheim | Maintains | Buy → Buy | — | $230.40 | $229.28 | -0.5% | +2.2% | +2.7% | +2.2% | +2.0% | +3.5% |
| Dec 15 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $226.33 | $227.85 | +0.7% | +1.0% | -0.7% | -1.6% | -0.9% | -0.7% |
| Oct 23 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $218.10 | $217.60 | -0.2% | +2.1% | +2.3% | +1.3% | -0.6% | -1.9% |
| Oct 22 | TD Cowen | Maintains | Buy → Buy | — | $220.77 | $222.50 | +0.8% | -1.2% | +0.9% | +1.0% | +0.1% | -1.8% |
| Oct 22 | Barclays | Maintains | Overweight → Overweight | — | $220.77 | $222.50 | +0.8% | -1.2% | +0.9% | +1.0% | +0.1% | -1.8% |
| Oct 8 | Rothschild & Co | Downgrade | Buy → Neutral | — | $208.77 | $206.90 | -0.9% | -1.8% | -2.1% | -3.0% | -1.7% | -1.3% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $211.71 | $212.51 | +0.4% | -1.4% | -3.2% | -3.4% | -4.4% | -3.1% |
| Sep 22 | BofA Securities | Maintains | Buy → Buy | — | $193.29 | $191.90 | -0.7% | -1.5% | -1.8% | -3.8% | -6.1% | -4.4% |
| Jul 23 | UBS | Maintains | Buy → Buy | — | $189.91 | $200.52 | +5.6% | +4.2% | +6.8% | +8.2% | +6.9% | +8.9% |
| Jul 23 | Guggenheim | Maintains | Buy → Buy | — | $189.91 | $200.52 | +5.6% | +4.2% | +6.8% | +8.2% | +6.9% | +8.9% |
| Jul 23 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $189.91 | $200.52 | +5.6% | +4.2% | +6.8% | +8.2% | +6.9% | +8.9% |
| Jul 23 | Baird | Maintains | Outperform → Outperform | — | $189.91 | $200.52 | +5.6% | +4.2% | +6.8% | +8.2% | +6.9% | +8.9% |
| Jul 18 | Baird | Maintains | Outperform → Outperform | — | $194.79 | $195.66 | +0.4% | -2.4% | -3.4% | -2.5% | +1.6% | +4.1% |
| Jul 11 | Scotiabank | Upgrade | Sector Perform → Sector Outperform | — | $205.51 | $205.51 | +0.0% | -0.3% | -3.8% | -6.2% | -5.9% | -5.2% |
| Jul 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $199.63 | $199.18 | -0.2% | +0.5% | +0.7% | +2.9% | +2.6% | -0.9% |
| Jun 24 | Barclays | Maintains | Overweight → Overweight | — | $196.34 | $197.35 | +0.5% | +0.6% | +2.4% | +2.6% | +1.3% | +0.6% |
| Apr 23 | Goldman Sachs | Maintains | Buy → Buy | — | $192.07 | $200.02 | +4.1% | +2.2% | +2.3% | +2.6% | +2.0% | +3.6% |
| Apr 23 | Guggenheim | Maintains | Buy → Buy | — | $192.07 | $200.02 | +4.1% | +2.2% | +2.3% | +2.6% | +2.0% | +3.6% |
| Apr 23 | UBS | Maintains | Buy → Buy | — | $192.07 | $200.02 | +4.1% | +2.2% | +2.3% | +2.6% | +2.0% | +3.6% |
| Apr 23 | RBC Capital | Maintains | Outperform → Outperform | — | $192.07 | $200.02 | +4.1% | +2.2% | +2.3% | +2.6% | +2.0% | +3.6% |
| Apr 23 | Baird | Maintains | Outperform → Outperform | — | $192.07 | $200.02 | +4.1% | +2.2% | +2.3% | +2.6% | +2.0% | +3.6% |
| Apr 22 | Barclays | Maintains | Overweight → Overweight | — | $184.96 | $198.24 | +7.2% | +3.8% | +6.1% | +6.2% | +6.6% | +5.9% |
| Apr 22 | JP Morgan | Maintains | Overweight → Overweight | — | $184.96 | $198.24 | +7.2% | +3.8% | +6.1% | +6.2% | +6.6% | +5.9% |
| Apr 22 | Jefferies | Maintains | Buy → Buy | — | $184.96 | $198.24 | +7.2% | +3.8% | +6.1% | +6.2% | +6.6% | +5.9% |
| Apr 16 | Baird | Maintains | Outperform → Outperform | — | $189.92 | $192.46 | +1.3% | +0.4% | -1.6% | -2.6% | +1.1% | +3.4% |
| Apr 10 | Barclays | Upgrade | Equal Weight → Overweight | — | $191.89 | $192.45 | +0.3% | -5.8% | -1.6% | +0.6% | -1.0% | -0.6% |
| Mar 14 | Stifel | Upgrade | Hold → Buy | — | $204.09 | $206.13 | +1.0% | +3.3% | +4.2% | +4.3% | +3.0% | +3.0% |
| Feb 3 | Raymond James | Downgrade | Outperform → Market Perform | — | $222.74 | $218.00 | -2.1% | -3.8% | -3.5% | -4.8% | -5.7% | -7.2% |
| Jan 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $223.73 | $225.00 | +0.6% | -0.3% | -0.4% | -4.2% | -3.9% | -5.2% |
| Jan 30 | RBC Capital | Maintains | Outperform → Outperform | — | $223.73 | $225.00 | +0.6% | -0.3% | -0.4% | -4.2% | -3.9% | -5.2% |
| Jan 30 | Barclays | Maintains | Equal Weight → Equal Weight | — | $223.73 | $225.00 | +0.6% | -0.3% | -0.4% | -4.2% | -3.9% | -5.2% |
| Jan 30 | Baird | Maintains | Outperform → Outperform | — | $223.73 | $225.00 | +0.6% | -0.3% | -0.4% | -4.2% | -3.9% | -5.2% |
| Jan 30 | Citigroup | Maintains | Buy → Buy | — | $223.73 | $225.00 | +0.6% | -0.3% | -0.4% | -4.2% | -3.9% | -5.2% |
| Jan 29 | Jefferies | Maintains | Buy → Buy | — | $247.84 | $235.02 | -5.2% | -9.7% | -10.0% | -10.1% | -13.5% | -13.2% |
| Jan 21 | Raymond James | Maintains | Outperform → Outperform | — | $238.36 | $239.95 | +0.7% | +2.4% | +2.4% | +3.1% | +3.1% | +5.1% |
| Jan 6 | Citigroup | Maintains | Buy → Buy | — | $234.84 | $234.15 | -0.3% | +1.4% | +1.8% | +1.4% | +0.1% | +2.1% |
| Dec 13 | BofA Securities | Upgrade | Neutral → Buy | — | $234.50 | $234.13 | -0.2% | +0.2% | -0.1% | -0.4% | -2.6% | -3.6% |
| Oct 31 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $242.32 | $243.89 | +0.6% | +1.4% | +2.2% | +2.0% | +3.2% | +2.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | SPOON ALAN GDir | — | Sell | 1,358 | $174.67 | $237K | 124,093 | +0.34% | — |
8-K · 7.01
! Medium
Masimo Corporation -- 8-K 7.01: Regulation FD Disclosure
Masimo disclosed material information via press release that investors should review in Exhibit 99.1 for details on developments affecting the company and its parent Danaher.
May 4
8-K
Masimo Corporation -- 8-K Filing
Masimo faces three stockholder lawsuits challenging its merger with Danaher, filed after the definitive proxy statement was disclosed, potentially delaying or jeopardizing the transaction's completion.
Apr 23
8-K
Danaher Corporation -- 8-K Filing
Danaher reported Q1 2026 results from continuing operations, with year-over-year comparisons providing investors insight into the conglomerate's operational performance across its diversified portfolio.
Apr 21
— 8-K filing (BAC, BNPQF, DHR)
Apr 17
8-K · 1.01
! Medium
Danaher Corporation -- 8-K 1.01: Financing / Debt Agreement
Danaher secured a credit facility extending to April 2027 with a one-year extension option available upon 0.50% fee payment, providing financial flexibility for capital management.
Apr 17
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An experienced life sciences executive is joining one of these companies, likely signaling leadership transition or strategic expansion in biotech/pharma sectors, which could impact growth direction and investor confidence.
Apr 7
8-K · 5.02
!!! Very High
Danaher Corporation -- 8-K 5.02: Executive Change
Danaher's appointment of a new executive signals potential strategic shifts in operations and governance; investors should monitor announcements regarding leadership responsibilities and company direction.
Feb 17
8-K
Danaher Corporation -- 8-K Filing
Danaher's 8-K disclosure likely addresses a material event—possibly an acquisition, dividend change, or executive transition—that could significantly impact earnings, cash flow, or strategic direction, warranting investor review.
Feb 10
Data updated apr 25, 2026 5:10am
· Source: massive.com